Barclays’s Protara Therapeutics TARA Stock Holding History

Barclays’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$63.6K	Buy	20,845 +2,238	+12%	+$8.72K	﹤0.01%	4490
2026 Q2	$71.1K	Sell	18,607 -29,655	-61%	-$141K	﹤0.01%	4192
2026 Q1	$251K	Sell	48,262 -6,795	-12%	-$40.2K	﹤0.01%	3558
2025 Q4	$293K	Buy	55,057 +9,537	+21%	+$53K	﹤0.01%	4140
2025 Q3	$198K	Sell	45,520 -10,119	-18%	-$32.8K	﹤0.01%	4321
2025 Q2	$169K	Sell	55,639 -37,600	-40%	-$130K	﹤0.01%	4377
2025 Q1	$397K	Hold	93,239	–	–	﹤0.01%	3664
2024 Q4	$492K	Buy	+93,239	New	+$301K	﹤0.01%	3832
2022 Q2	–	Sell	-2,510	Closed	-$13K	–	5260
2022 Q1	$13K	Buy	+2,510	New	+$13.2K	﹤0.01%	4552
2015 Q4	–	Sell	-1	Closed	-$1K	–	6545
2015 Q3	$1K	Sell	1 -3	-75%	-$1.86K	﹤0.01%	6599
2015 Q2	$2K	Buy	+4	New	+$2.47K	﹤0.01%	6819

Other funds holding TARA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.4B AUM 32.2% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Barclays's TARA Position: Q3 2026 in Review

Barclays increased its Protara Therapeutics (TARA) stake by 12% in Q3 2026, buying an estimated $8.72K and bringing the position to 20,845 shares worth $63.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4490.

Barclays first reported a position in TARA in Q2 2015 and has held it in 11 quarters since. The position peaked at $492K in Q4 2024. 38 funds tracked by Wall St. Rank hold TARA as of Q3 2026.

Barclays held 20,845 shares of Protara Therapeutics worth $63.6K as of Q3 2026.
Barclays bought 2,238 Protara Therapeutics shares in Q3 2026, an estimated $8.72K.
Protara Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4490 holding.
Barclays first reported a position in Protara Therapeutics in Q2 2015 and has held it in 11 quarters since.
Barclays's Protara Therapeutics position peaked at $492K in Q4 2024.
38 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.